Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Contenuto fornito da Stock Day Media. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Stock Day Media o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !
Vai offline con l'app Player FM !
Trend Micro Incorporated | Innovent Biologics, Inc.
Manage episode 421713632 series 180440
Contenuto fornito da Stock Day Media. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Stock Day Media o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Trend Micro Incorporated ( TYO: 4704 ; TSE: 4704 ), a global cybersecurity leader, announced plans to demo a new data center solution, using NVIDIA technology, for security-conscious business and government customers harnessing the power of AI. This is just one of multiple AI security solutions being shown for the first time at COMPUTEX 2024.
Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
For more information, please visit StockDayMedia.com
Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
For more information, please visit StockDayMedia.com
1487 episodi
Manage episode 421713632 series 180440
Contenuto fornito da Stock Day Media. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Stock Day Media o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Trend Micro Incorporated ( TYO: 4704 ; TSE: 4704 ), a global cybersecurity leader, announced plans to demo a new data center solution, using NVIDIA technology, for security-conscious business and government customers harnessing the power of AI. This is just one of multiple AI security solutions being shown for the first time at COMPUTEX 2024.
Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
For more information, please visit StockDayMedia.com
Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI), were published in the Journal of Clinical Oncology (JCO) and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
For more information, please visit StockDayMedia.com
1487 episodi
Todos los episodios
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.